COMPANY PROFILE

Xoc Pharmaceuticals

Explore full profile

A biopharmaceutical company based in Los Gatos, Calif

Los Gatos, United StatesFounded 2013Biotech & Life Sciences

Valuation $100–250M Last recorded · 2018

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Xoc Pharmaceuticals

Xoc Pharmaceuticals operates in the pharmaceutical and biotechnology sector, specializing in innovative drug delivery solutions for neurological conditions. The company primarily serves patients suffering from neurological disorders, leveraging advanced medical devices and drug-device combination products to enhance treatment efficacy and patient outcomes. Xoc Pharmaceuticals operates in a highly specialized market, focusing on the development, validation, and lifecycle management of pharmaceutical products. The business model revolves around extensive research and development (R&D) activities, followed by the commercialization of proprietary drug delivery systems. Revenue generation is primarily through the sale of these specialized products and potential licensing agreements with larger pharmaceutical companies. The company has secured significant funding, including a $30 million Series A financing led by NEA, to support its R&D and commercialization efforts. Key clients include healthcare providers, hospitals, and specialty clinics focused on treating neurological conditions.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2013
Headquarters: Los Gatos, United States
Employees: 2
Open positions: None listed
Dealroom signal: 53.9/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Risk Management, Biotechnology, Arts & Culture, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Feb 2018	$30M	$120M	NEA	—

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Xoc Pharmaceuticals website traffic

Latest recorded traffic for Xoc Pharmaceuticals is 390 monthly website visits, up 105.3% over the last three months. Xoc Pharmaceuticals's team grew 0% over the past year.

Latest monthly visits390 3-month web change+105.3% 1-year team growth0%

Monthly website visitsOct 2017–Jun 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
QUQuanDxMolecular Diagnostics Innovator - A personalized and precision diagnostic company in the San Francisco bay area	San Jose, United States	Operational	1	$4.3M	$12M
CRCell ReservesCanadian biopharmaceutical company developing a biomolecular shield for therapeutic molecules	Ottawa, Canada	Operational
RERestorbioInnovative medicines targeting aging biology to prevent or treat age-related diseases	Boston, United States	Operational
OPOre PharmaceuticalsOre Pharmaceuticals uses a proprietary system, based on analysis of gene expression and gene regulation, to discover drug	Indianapolis, United States	Operational
ONOneSkinA longevity company on a mission to transform the way we think about skin and aging	San Francisco, United States	Operational
FRFirma Clinical ResearchResearch organization providing services to the biopharmaceutical industry	Chicago, United States	Operational
BIBioTheranosticsExtensive research generates high-complexity molecular tools that help physicians execute more informed treatment decisions	San Diego, United States	Acquired
STSymbiomix TherapeuticsBiopharmaceutical company bringing innovative medicines to market for prevalent gynecological infections than can have serious health consequences	Newark, United States	Acquired